Skip to main content

Table 2 Serum bile acids and fold changes in the studied groups

From: Role of bile acids in the prediction of hepatocellular carcinoma in HCV-induced liver cirrhosis

BA NHC NCLD CLD HCC F, NCLD F, CLD F, HCC
CA 0.20 ± 0.3 0.6 ± 1.7 NS 0.5 ± 0.86* 1.7 ± 4* 3* 3* 9*
CDCA 0.38 ± 0.51 0.73 ± 1.2 NS 1.45 ± 1.91* 5.1 ± 14* 2* 4* 13*
DCA 0.15 ± 0.16 0.19 ± 0.11* 0.31 ± 0.40 NS 0.25 ± 0.39 NS 1 2* 2*
LCA 0.01 ± 0.03 0.03 ± 0.05* 0.05 ± 0.09* 0.11 ± 0.20* 3* 4* 9*
UDCA 0.04 ± 0.1 0.04 ± 0.08 NS 1.56 ± 5.01* 1.99 ± 6* 1 38* 48*
GCA 0.24 ± 0.33 0.43 ± 0.77 NS 3.77 ± 4.06* 8.4 ± 13* 2* 16* 35*
GCDCA 0.45 ± 0.66 0.86 ± 1.04* 7.7 ± 11.5* 12.5 ± 17* 2* 17* 29*
GDCA 0.24 ± 0.36 0.26 ± 0.33 NS 1.48 ± 2.9* 1.72 ± 7.2 NS 1 6* 7*
GUDCA 0.15 ± 0.2 0.07 ± 0.12* 5.2 ± 12.9* 9.4 ± 30* 0.5 35* 38*
TCA 0.01 ± 0.05 0.04 ± 0.09* 1.7 ± 2.7* 7.05 ± 16* 3* 113* 473*
TCDCA 0.11 ± 0.18 0.07 ± 0.15 NS 4.77 ± 13.8* 9.1 ± 16* 0.7 44* 83*
TDCA 0.07 ± 0.15 0.02 ± 0.03 NS 0.19 ± 0.36 NS 1.6 ± 6 NS 0.3 3* 24*
TLCA 0.006 ± 0.028 0.001 ± 0.002* 0.02 ± 0.07* 0.08 ± 0.3* 0.3 4* 13*
TUDCA 0.04 ± 0.12 0.01 ± 0.02NS 0.09 ± 0.37 NS 0.90 ± 5.17 NS 0.3 2* 18*
  1. NHC normal healthy control, NCLD noncirrhotic liver disease, CLD cirrhotic liver diseases, HCC hepatocellular carcinoma. N = 50, number of each group, values: mean ± standard deviation of bile acids (μM/L); F, fold changes relative to NHC. *P value < 0.05 indicates significance when NHC compared to either NCLD, CLD, or HCC. NSP value > 0.05 indicates significance when NHC compared to either NCLD, CLD, or HCC
  2. CA cholic acid, CDCA chenodeoxycholic acid, DCA deoxycholic acid, LCA lithocholic acid, UDCA ursodeoxycholic acid, GCA glycholic acid, GCDCA glycochenodeoxycholic acid, GDCA glycodeoxycholic acid, GUDCA glycoursodeoxycholic acid, TCA taurocholic acid, TCDCA taurochenodeoxycholic acid, TDCA taurodeoxycholic acid, TLCA taurolithocholic acid, TUDCA tauroursodeoxycholic acid